Global pharmaceutical manufacturer, Aesica, experienced significant growth in 2011, doubling both its turnover and its workforce and forming a number of long-term strategic partnerships with customers such as UCB and Noramco.

As the contract manufacturing market continues to grow apace and with CMOs’ global revenue predicted to more than double by 2021[1], the challenge for contract manufacturers is to enhance their offering and provide integrated global supply chain solutions.

Since its inception in 2004, Aesica has sought to become the preferred supplier of APIs and formulated products to the global pharmaceutical and biotechnology industry. The firm’s objective to establish itself as a fully integrated CMO was fully realized in 2010 with the introduction of its formulation development team. This enabled Aesica to offer clients its expertise in transitioning lead candidate materials out of medicinal chemistry into GMP development. Now, the parallel approach between API development and formulation development teams at Aesica delivers a more swift and efficient preclinical and clinical development process for its clients.

Dr. Robert Hardy, Chief Executive, Aesica, said

“While there are significant cost savings in working with one single manufacturer, other considerable inherent advantages are derived from an integrated project team approach. We aim to develop strategic partnerships with our clients and our integrated service reassures them we have total familiarity with their API, which leads to reduced timelines and expenditure. During the optimisation process, we can provide non-GMP grade material to our formulation development team so that early preformulation evaluation can occur simultaneously. Once the GMP material has been synthesised, we can then manufacture clinical trial supply while conducting stability testing.”

“In addition, we can manufacture API to SafeBridge® Category 3, produce controlled drugs and manage the formulation of all dosage forms, which has enabled us to create a niche offering within the marketplace.”

With plans to acquire manufacturing assets in North America later this year, Aesica is predicting a significant increase in its sales for 2012 and plans to develop further strategic alliances with both emerging biotechnology companies and established pharma organisations.

[1], August 2011

  • News
  • Case Studies
  • Pages
  • Blogs
  • Locations
  • Experts